Splitting Metoprolol Succinate Extended-Release Tablets
Metoprolol succinate extended-release tablets are scored and can be divided, with the whole or half tablet swallowed whole and not chewed or crushed 1. This is explicitly stated in the FDA labeling and represents the most authoritative guidance on this practice.
Key Points from FDA Labeling
The FDA-approved prescribing information clearly permits tablet splitting for metoprolol succinate extended-release formulations 1. The critical requirements are:
- The tablet is scored (designed with a dividing line)
- Half tablets must be swallowed whole - not chewed, crushed, or further divided
- Dosing remains once daily after splitting
This guidance applies across all approved indications including hypertension (starting doses 25-100 mg daily), angina (starting 100 mg daily), and heart failure (starting 12.5-25 mg daily depending on NYHA class) 1.
Clinical Context from Guidelines
Major heart failure guidelines support the use of metoprolol succinate extended-release at doses ranging from 12.5 mg to 200 mg daily 2, 3. The 2017 ACC/AHA guideline documents mean doses achieved in clinical trials of 159 mg daily, with maximum studied doses of 200 mg daily 2. Cardioselective beta-blockers like metoprolol succinate are preferred in patients with concurrent lung disease 3, making dose flexibility through splitting particularly valuable.
Important Caveats About Tablet Splitting
While FDA-approved for scored tablets, research reveals significant concerns:
- Dose variability exists: Studies show 23.9-33.3% of metoprolol succinate half-tablets fall outside USP specifications for drug content 4
- Weight loss occurs: Average 1% weight loss during splitting, though this varies 4
- Non-homogeneous distribution: The multiple-unit pellet system within these tablets can lead to uneven drug distribution between halves 5
- Dissolution profile changes: Crushing (not splitting) dramatically alters release characteristics and should never be done 6
The key distinction: splitting scored tablets is acceptable per FDA labeling, but the halves must remain intact and be swallowed whole 1.
Monitoring Recommendations
When patients take half tablets of metoprolol succinate:
- Monitor heart rate and blood pressure at each dose adjustment, typically weekly intervals 1
- Watch for symptomatic bradycardia - if it occurs, reduce the dose 1
- In heart failure patients: Monitor for signs of worsening HF (weight gain, increased dyspnea) during titration 1
- Assess clinical response after 1 week at each dose level for hypertension 1
Practical Algorithm
- Verify the tablet is scored - all commercial metoprolol succinate ER tablets should be
- Use a tablet splitter rather than breaking by hand, especially in older adults who may struggle with manual splitting 7
- Instruct patient to swallow half-tablet whole - emphasize not chewing or crushing 1
- Maintain once-daily dosing schedule - preferably with or immediately following meals 1
- Titrate gradually - increase dose at weekly or longer intervals based on clinical response 1
Common Pitfalls to Avoid
- Never crush or chew the extended-release formulation - this destroys the controlled-release mechanism and causes rapid, potentially dangerous drug release 1, 6
- Don't split unscored tablets - only FDA-approved scored formulations should be divided
- Avoid abrupt discontinuation - taper over 1-2 weeks if stopping, especially in angina patients 1
- Don't advance doses during acute HF decompensation - stabilize with diuretics first 1
The practice is FDA-sanctioned for scored tablets when halves are swallowed intact, though clinicians should be aware of potential dose variability between tablet halves.